DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 0.00 0.00%
S&P 500 2,063.50 10.75 0.52%
market minute promo


3.39 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $3.39 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $3.39
Daily Range $0.00 - $0.00
52-Week Range $2.97 - $10.29
Market Cap $351.5M
P/E Ratio -4.77
Dividend (Yield) $0.00 (0.0%)
Volume 0
Average Daily Volume 1,766,087
Current FY EPS -$0.78





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

For This Obesity Drug, Europe Trumps the U.S.

Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.

Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday

Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape

Janssen Is Working Its Way Toward Anti-Obesity

EnteroMedics May Enter The Obesity Space - What Does It Mean?

The 52-Week Low Club for Monday

What's Driving Orexigen Therapeutics Higher?

Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog

Bel-Phen Pilot Study News, Hold On To Your Shares

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?

Arena Pharmaceuticals stock has fallen hard after a slower than expected launch of its fat-fighting pill Belviq. During its third-quarter conference call, though, management gave three reasons investors should be optimistic moving forward.

See More VVUS News...

VVUS's Top Competitors

VVUS $3.39 (0.00%)
Current stock: VVUS
JNJ $107.86 (0.00%)
Current stock: JNJ
NVS $94.98 (0.00%)
Current stock: NVS
RHHBY $37.33 (-0.93%)
Current stock: RHHBY